|
at 08:10 |
|
|
Positive results from the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) ?demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free...
|
|
at 08:05 |
|
|
Gilead Sciences, Inc. and Arcus Biosciences, Inc. today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine receptor antagonist, plus anti-PD-1 monoclonal antibody...
|
|
at 08:05 |
|
|
ASCO Annual Meeting ? Massive Bio, a renowned leader in AI-driven oncology solutions and Mika Health, the premier oncology digital therapeutic platform, today announced a partnership to significantly expand patient access to psycho oncology services,...
|
|
at 08:05 |
|
|
Detailed positive results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of...
|
|
at 08:05 |
|
|
Detailed positive results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to...
|
|
at 08:00 |
|
|
OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced a research study with Dana-Farber Cancer Institute, a world leader in adult and pediatric cancer treatment and research, to...
|
|
|
